We are live on ! Find out more
TGTX icon

TG Therapeutics
TGTX

67 hedge funds and large institutions have $122M invested in TG Therapeutics in 2014 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 25 increasing their positions, 19 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

800% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 2

680% more call options, than puts

Call options by funds: $7.49M | Put options by funds: $960K

52% more capital invested

Capital invested by funds: $80.2M → $122M (+$41.7M)

32% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 19

31% more funds holding

Funds holding: 51 → 67 (+16)

Holders
67
Holders Change
+16
Holders Change %
+31.37%
% of All Funds
1.93%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
18
Increased
25
Reduced
19
Closed
2
Calls
$7.49M
Puts
$960K
Net Calls
+$6.53M
Net Calls Change
+$5.01M

Top Buyers

Rank Fund Capital Flow
1
VAM
Visium Asset Management
New York
+$4.03M
2
Millennium Management
Millennium Management
New York
+$1.73M
3
TC
TFS Capital
Pennsylvania
+$1.07M
4
CCI
Columbus Circle Investors
+$1.02M
5
Invesco
Invesco
Georgia
+$899K

Top Sellers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
-$3.52M
2
SFM
Sphera Funds Management
Israel
-$895K
3
SGAM
Smith Group Asset Management
Texas
-$721K
4
Morgan Stanley
Morgan Stanley
New York
-$592K
5
Jennison Associates
Jennison Associates
New York
-$307K
Name Holding Trade Value Shares
Change 		Change in
Stake
Citadel Advisors
51
Citadel Advisors
Florida
$51K -$205K -32,129 -85%
SO
52
STRS Ohio
Ohio
$50K – – –
Wells Fargo
53
Wells Fargo
California
$34K +$22.7K +3,545 +88,625%
U
54
UBS
Switzerland
$28K -$18.1K -2,838 -49%
LTFS
55
Ladenburg Thalmann Financial Services
Florida
$26K – – –
VFA
56
Virtus Fund Advisers
Connecticut
$19K +$12.8K +2,003 New
TRCT
57
Tower Research Capital (TRC)
New York
$8K -$8.75K -1,369 -63%
BNP Paribas Financial Markets
58
BNP Paribas Financial Markets
France
$6.35K +$499 +78 +13%
BlackRock
59
BlackRock
New York
$6K +$3.84K +600 New
Bank of Montreal
60
Bank of Montreal
Ontario, Canada
$4K -$66.1K -10,340 -96%
PCM
61
Prelude Capital Management
New York
$4K -$54.9K -8,580 -95%
Barclays
62
Barclays
United Kingdom
$4K -$1.77K -277 -41%
Janus Henderson Group
63
Janus Henderson Group
United Kingdom
$3K -$6 -1 -0.3%
Citigroup
64
Citigroup
New York
$2K -$17.4K -2,720 -93%
TDC
65
Thompson Davis & Co
Virginia
$2K -$1.6K -250 -50%
JC
66
JBF Capital
Colorado
– -$115K -16,676 Closed
Ameriprise
67
Ameriprise
Minnesota
– +$128 +20 New
1 2
3

TGTX Hedge Fund Activity: Q2 2014 in Review

67 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in TG Therapeutics (TGTX) for Q2 2014, worth a combined $122M — up 52% from $80.2M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new TGTX positions and 2 closed out — a net gain of 16 holders — while 25 added to existing stakes and 19 trimmed.

The largest buyer was Visium Asset Management, opening a new position worth an estimated $4.03M. The largest seller was JP Morgan Chase, cutting an estimated $3.52M.

  • 67 institutional investors held TG Therapeutics (TGTX) as of Q2 2014, up from 51 in Q1 2014.
  • Funds reported $122M of TG Therapeutics stock for Q2 2014, up 52% quarter-over-quarter.
  • 18 funds opened new TG Therapeutics positions in Q2 2014 and 2 closed out, a net change of +16 holders.
  • The largest TG Therapeutics buyer in Q2 2014 was Visium Asset Management, an estimated $4.03M added.
  • The largest TG Therapeutics seller in Q2 2014 was JP Morgan Chase, an estimated $3.52M sold.

Based on aggregated 13F filings for Q2 2014.